HUMAN C1-ESTERASE INHIBITOR

Summary

Human C1-Esterase Inhibitor (CHEMBL4297549) is an approved protein (ATC B06AC01); indicated across 6 conditions including hereditary angioedema and angioedema.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: B06AC01
• Indications: 6 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297549
Name	HUMAN C1-ESTERASE INHIBITOR
Type	Protein
Max phase	4
ATC	B06AC01

Also known as: Berinert, C1 inhibitor (human), C1 inhibitor human, plasma derived, Cetor, Cinryze, RVG-19303

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hereditary angioedema	4	MONDO:0019623	MONDO:0019623
angioedema	3	MONDO:0010481	EFO:0005532
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
kidney failure	1	MONDO:0001106	EFO:1002048
neuromyelitis optica	1	MONDO:0019100	EFO:0004256
chronic kidney disease	1	MONDO:0005300	EFO:0003884

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	3
PHASE4	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00914966	PHASE4	COMPLETED	A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE
NCT01467947	PHASE4	COMPLETED	Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert
NCT01843530	PHASE3	COMPLETED	Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema
NCT02052141	PHASE3	COMPLETED	Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
NCT02865720	PHASE3	COMPLETED	Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
NCT06919003	PHASE2	RECRUITING	Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
NCT01095497	PHASE2	COMPLETED	A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
NCT01095510	PHASE2	COMPLETED	CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
NCT04696146	PHASE1/PHASE2	COMPLETED	Berinert (C1INH) vs Placebo for DGF/IRI
NCT05010876	PHASE2	COMPLETED	Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).
NCT01760343	PHASE1	COMPLETED	A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor
NCT02435732	PHASE1	UNKNOWN	CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).